Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Casey Maguire
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Chameleon Biosciences, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Maguire holds equity in Chameleon Biosciences, Inc., a private company developing an enveloped Adeno Associated Virus (AAV) vector platform technology for repeated dosing of systemic gene therapy. The research project involves manipulating tumor-associated cells using systemically administered AAV and other vectors carrying transgene cassettes under promoters that are strongly up-regulated in cells near the tumor, but not in the same cell types in other parts of the brain. The research results on AAV could be of interest to the company. The Partners Committee on Outside Activities review panel evaluated the financial interest in connection with this research projects and determined that, based on the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
The power of extracellular vesicles in glioblastoma
Narrative A seasoned team will elaborate on extracellular vesicles released from glioblastoma for use as biomarkers of clinical response. Studies will focus on how these extracellular vesicles subjugate normal cells in the microenvirons in support of tumor growth, and how these insights can be exploited to design novel modes of therapy.
Filed on September 07, 2018.
Tell us what you know about Casey Maguire's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Casey Maguire”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Casey Maguire | Massachusetts General Hospital | Conflict of Interest | Chameleon Biosciences, Inc. | Value cannot be readily determined |
| Casey Maguire | Harvard Medical School | Conflict of Interest | Chameleon Biosciences, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.